SG11201906192SA - Methods of treating cancer with anti-pd-1 antibodies - Google Patents
Methods of treating cancer with anti-pd-1 antibodiesInfo
- Publication number
- SG11201906192SA SG11201906192SA SG11201906192SA SG11201906192SA SG11201906192SA SG 11201906192S A SG11201906192S A SG 11201906192SA SG 11201906192S A SG11201906192S A SG 11201906192SA SG 11201906192S A SG11201906192S A SG 11201906192SA SG 11201906192S A SG11201906192S A SG 11201906192SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- tesaro
- waltham
- suite
- street north
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 abstract 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000003692 ilium Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762444336P | 2017-01-09 | 2017-01-09 | |
US201762477423P | 2017-03-27 | 2017-03-27 | |
US201762491220P | 2017-04-27 | 2017-04-27 | |
US201762556386P | 2017-09-09 | 2017-09-09 | |
PCT/US2018/013029 WO2018129559A1 (en) | 2017-01-09 | 2018-01-09 | Methods of treating cancer with anti-pd-1 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906192SA true SG11201906192SA (en) | 2019-08-27 |
Family
ID=61188903
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906192SA SG11201906192SA (en) | 2017-01-09 | 2018-01-09 | Methods of treating cancer with anti-pd-1 antibodies |
SG10201913075RA SG10201913075RA (en) | 2017-01-09 | 2018-01-09 | Methods of treating cancer with anti-pd-1 antibodies |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913075RA SG10201913075RA (en) | 2017-01-09 | 2018-01-09 | Methods of treating cancer with anti-pd-1 antibodies |
Country Status (21)
Country | Link |
---|---|
US (2) | US11407830B2 (de) |
EP (2) | EP3565844B8 (de) |
JP (2) | JP7110206B6 (de) |
KR (1) | KR102606252B1 (de) |
CN (1) | CN110382545A (de) |
AU (1) | AU2018206481A1 (de) |
BR (1) | BR112019014187A2 (de) |
CA (1) | CA3049440A1 (de) |
DK (1) | DK3565844T3 (de) |
ES (1) | ES2945745T3 (de) |
FI (1) | FI3565844T3 (de) |
HU (1) | HUE061842T2 (de) |
IL (1) | IL267804B1 (de) |
MA (1) | MA47208A (de) |
MX (1) | MX2019008207A (de) |
PL (1) | PL3565844T3 (de) |
PT (1) | PT3565844T (de) |
SG (2) | SG11201906192SA (de) |
TW (1) | TWI767976B (de) |
WO (1) | WO2018129559A1 (de) |
ZA (1) | ZA201904316B (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101855381B1 (ko) | 2008-04-09 | 2018-05-09 | 제넨테크, 인크. | 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법 |
CN110023337B (zh) | 2016-10-11 | 2024-01-05 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
BR112019008859A2 (pt) * | 2016-11-01 | 2019-07-09 | Anaptysbio Inc | anticorpos direcionados contra a morte programada 1 (pd-1) |
CN110382545A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗pd-1抗体治疗癌症的方法 |
CN110913911A (zh) | 2017-05-18 | 2020-03-24 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
EA202090573A1 (ru) | 2017-09-26 | 2020-09-07 | Тесаро, Инк. | Составы нирапариба |
MA50409A (fr) | 2017-09-30 | 2020-08-26 | Tesaro Inc | Polythérapies pour le traitement du cancer |
EA202090655A1 (ru) | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
TW202024638A (zh) * | 2018-09-04 | 2020-07-01 | 美商泰沙羅公司 | 治療癌症之方法 |
ES2967517T3 (es) | 2018-10-03 | 2024-04-30 | Tesaro Inc | Sales de niraparib |
US20210347758A1 (en) | 2018-10-03 | 2021-11-11 | Tesaro, Inc. | Crystalline Forms of Niraparib Freebase |
US20200199567A1 (en) * | 2018-12-20 | 2020-06-25 | Medimmune, Llc | Methods for selection and expansion of t cells expressing pd-1 |
US11613564B2 (en) * | 2019-05-31 | 2023-03-28 | ALX Oncology Inc. | Methods of treating cancer |
WO2021126657A1 (en) | 2019-12-18 | 2021-06-24 | Tesaro, Inc. | Biopharmaceutical compositions and related methods |
US20230094843A1 (en) * | 2019-12-31 | 2023-03-30 | Fukang (Shanghai) Health Technology Co., Ltd | Pharmaceutical combination for treating tumors and application thereof |
JP2023512023A (ja) | 2020-01-28 | 2023-03-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 併用療法及びその使用及び方法 |
EP4060346A4 (de) * | 2020-02-18 | 2023-12-13 | Innobation Bio Co., Ltd. | Begleit-diagnosebiomarkerzusammensetzung und begleitdiagnosekit damit |
AU2021293507A1 (en) * | 2020-06-18 | 2023-02-02 | F. Hoffmann-La Roche Ag | Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists |
WO2022025482A1 (ko) * | 2020-07-29 | 2022-02-03 | 재단법인 아산사회복지재단 | 스트렙토니그린 및 면역관문 억제제를 유효성분으로 포함하는 대장암 예방 및 치료용 조성물 |
WO2023076668A1 (en) * | 2021-10-29 | 2023-05-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for treatment of cancer |
WO2023153763A1 (ko) * | 2022-02-08 | 2023-08-17 | 고려대학교 산학협력단 | C-met의 에피토프 및 hif1alpha의 에피토프를 포함하는 암 백신 및 이의 용도 |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
JP3150340B2 (ja) | 1990-11-13 | 2001-03-26 | イムネクス コーポレイション | 二機能選択可能融合遺伝子 |
AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
ES2402546T3 (es) | 2000-06-28 | 2013-05-06 | Genetics Institute, Llc | Moléculas PD-L2: nuevos ligandos de PD-1 y usos de lso mismos |
FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
KR20030066657A (ko) | 2000-11-15 | 2003-08-09 | 오노 야꾸힝 고교 가부시키가이샤 | Pd-1 결손 마우스 및 그 용도 |
AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
WO2002079499A1 (en) | 2001-04-02 | 2002-10-10 | Wyeth | Pd-1, a receptor for b7-4, and uses therefor |
JP4249013B2 (ja) | 2001-07-31 | 2009-04-02 | 佑 本庶 | Pd−1に対し特異性を有する物質 |
EP1456652A4 (de) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | Immunzellenaktivierung modulierende substanzen und verwendungsverfahren dafür |
JP4409430B2 (ja) | 2002-07-03 | 2010-02-03 | 小野薬品工業株式会社 | 免疫賦活組成物 |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
PL2439273T3 (pl) | 2005-05-09 | 2019-08-30 | Ono Pharmaceutical Co., Ltd. | Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami |
KR101514463B1 (ko) | 2005-06-08 | 2015-04-28 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(pd-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
US8901281B2 (en) | 2005-06-17 | 2014-12-02 | Merck Sharp & Dohme Corp. | ILT3 binding molecules and uses therefor |
JP5093097B2 (ja) | 2006-03-03 | 2012-12-05 | 小野薬品工業株式会社 | 細胞表面機能分子の細胞外領域多量体 |
CN101611054B (zh) * | 2006-10-02 | 2013-12-25 | Ac免疫有限公司 | 针对淀粉状蛋白β的人源化抗体 |
CA3045637A1 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
EP2109608B1 (de) | 2007-01-10 | 2011-03-23 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Amidsubstituierte indazole als poly-(adp-ribose)-polymerase (parp)-hemmer |
JP2010520748A (ja) | 2007-02-20 | 2010-06-17 | アナプティスバイオ インコーポレイティッド | 体細胞超変異系 |
JP2010524846A (ja) | 2007-03-20 | 2010-07-22 | イーライ リリー アンド カンパニー | 抗スクレロスチン抗体 |
CN103641919B (zh) | 2007-05-30 | 2017-04-05 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
US20120269806A1 (en) | 2007-08-21 | 2012-10-25 | The General Hospital Corporation | Methods of inducing tolerance |
US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
BRPI0906020A2 (pt) | 2008-01-08 | 2015-06-30 | Merck Sharp & Dohme | Sais farmaceuticamente aceitáveis de 2-{4-[ (3s) - piperidina-3-il ] fenil} -2h - indazol - 7 - carboxamida, uso e método de tratamento |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
JP5945096B2 (ja) | 2008-07-04 | 2016-07-05 | 小野薬品工業株式会社 | 抗ヒトpd−1抗体の癌に対する治療効果を最適化するための判定マーカーの使用 |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
EA023148B1 (ru) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
EP2342228B1 (de) | 2008-09-12 | 2017-09-06 | Oxford University Innovation Limited | Pd-1-spezifische antikörper und anwendungen davon |
US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
CA2998281C (en) | 2008-09-26 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1 antobodies and uses therefor |
KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제 |
CN102282265B (zh) | 2008-11-28 | 2020-07-24 | 埃默里大学 | 用于治疗传染病和肿瘤的方法 |
JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | Pd−1抗体およびpd−l1抗体ならびにその使用 |
US8637019B2 (en) * | 2009-11-04 | 2014-01-28 | Merck Sharp & Dohme Corp. | Engineered anti-TSLP antibody |
LT2519543T (lt) | 2009-12-29 | 2016-10-10 | Emergent Product Development Seattle, Llc | Heterodimerus rišantys baltymai ir jų panaudojimas |
WO2011100841A1 (en) | 2010-02-16 | 2011-08-25 | Valorisation-Recherche, Limited Partnership | Pd-1 modulation and uses thereof for modulating hiv replication |
US8993731B2 (en) | 2010-03-11 | 2015-03-31 | Ucb Biopharma Sprl | PD-1 antibody |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
JP2013522313A (ja) * | 2010-03-17 | 2013-06-13 | アボツト・リサーチ・ベー・フエー | 抗神経成長因子(ngf)抗体組成物 |
EP2547781A4 (de) | 2010-03-17 | 2014-04-23 | Anaptysbio Inc | Verfahren zur herstellung von transkripten mithilfe verborgener splice-orte |
WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
CA2805564A1 (en) | 2010-08-05 | 2012-02-09 | Stefan Jenewein | Anti-mhc antibody anti-viral cytokine fusion protein |
US20130217656A1 (en) | 2010-08-12 | 2013-08-22 | Beth Israel Deaconess Medical Center Inc | Methods and compositions for diagnosing and treating lupus |
WO2012031122A2 (en) | 2010-09-03 | 2012-03-08 | Immport Therapeutics, Inc. | Methods and compositions for the diagnosis and treatment of cancer and autoimmune disorders |
US9029315B2 (en) | 2010-11-11 | 2015-05-12 | The University Of Hong Kong | Soluble PD-1 variants, fusion constructs, and uses thereof |
JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
KR102289394B1 (ko) | 2011-03-31 | 2021-08-13 | 머크 샤프 앤드 돔 코포레이션 | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 |
TWI496886B (zh) | 2011-06-24 | 2015-08-21 | Taipei Veteran General Hospital | 提升感染性與惡性疾病之治療之免疫反應 |
EP3939613A1 (de) | 2011-08-11 | 2022-01-19 | ONO Pharmaceutical Co., Ltd. | Therapeutikum für autoimmunerkrankungen mit pd-1-agonist |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
CA2873402C (en) | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
WO2013177102A2 (en) | 2012-05-21 | 2013-11-28 | Felder Mitchell S | Treatment of cancer by manipulating the immune system |
WO2013174997A1 (en) | 2012-05-25 | 2013-11-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of refractory haematological malignancies |
CA2874144C (en) | 2012-05-31 | 2023-12-19 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
DK2992017T3 (da) | 2013-05-02 | 2021-01-25 | Anaptysbio Inc | Antistoffer rettet mod programmeret død-1 (pd-1) |
DK3081576T3 (da) | 2013-12-12 | 2019-10-21 | Shanghai hengrui pharmaceutical co ltd | Pd-1-antistof, antigenbindende fragment deraf og medicinsk anvendelse deraf |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
EP3114144A1 (de) * | 2014-03-05 | 2017-01-11 | Bristol-Myers Squibb Company | Behandlung von nierenkrebs mittels einer kombination aus einem antikörper gegen pd-1 und einem anderen krebsmittel |
AU2015229103C9 (en) | 2014-03-14 | 2020-11-26 | Immutep S.A.S | Antibody molecules to LAG-3 and uses thereof |
CA2943167A1 (en) | 2014-03-24 | 2015-10-01 | University Of Southampton | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
RS60097B1 (sr) | 2014-06-19 | 2020-05-29 | Regeneron Pharma | Ne-humane životinje koje imaju humanizovani gen za programiranu ćelijsku smrt 1 |
DK3177644T3 (da) | 2014-08-05 | 2021-01-11 | MabQuest SA | Immunologiske reagenser, som binder til PD-1 |
WO2016029073A2 (en) * | 2014-08-22 | 2016-02-25 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
US20170209574A1 (en) | 2014-10-03 | 2017-07-27 | Novartis Ag | Combination therapies |
WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
MA41218A (fr) | 2014-12-19 | 2017-10-24 | Advaxis Inc | Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr |
US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
CA2971734A1 (en) | 2014-12-22 | 2016-06-30 | Enumeral Biomedical Holdings, Inc. | Anti-pd-1 antibodies |
LT3240801T (lt) | 2014-12-31 | 2021-02-25 | Checkmate Pharmaceuticals, Inc. | Kombinuota navikų imunoterapija |
JP6313530B1 (ja) | 2015-01-16 | 2018-04-18 | アカデミア シニカAcademia Sinica | 標的化成分及びエフェクター成分を有する分子構築物 |
MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
EP3283107B1 (de) * | 2015-04-17 | 2020-05-27 | Bristol-Myers Squibb Company | Zusammensetzungen mit einer kombination aus ipilimumab und nivolumab |
US20160362489A1 (en) * | 2015-04-28 | 2016-12-15 | Bristol-Myers Squibb Company | Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody |
LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
IL263925B2 (en) | 2016-06-29 | 2023-12-01 | Tesaro Inc | Methods of treating ovarian cancer |
BR112019008859A2 (pt) * | 2016-11-01 | 2019-07-09 | Anaptysbio Inc | anticorpos direcionados contra a morte programada 1 (pd-1) |
EA201990741A1 (ru) * | 2016-11-29 | 2019-11-29 | Антитела, направленные против белка-1 запрограммированной смерти (pd-1) | |
US11926665B2 (en) | 2017-01-09 | 2024-03-12 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
CN110382545A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗pd-1抗体治疗癌症的方法 |
MA50409A (fr) | 2017-09-30 | 2020-08-26 | Tesaro Inc | Polythérapies pour le traitement du cancer |
-
2018
- 2018-01-09 CN CN201880016132.XA patent/CN110382545A/zh active Pending
- 2018-01-09 WO PCT/US2018/013029 patent/WO2018129559A1/en unknown
- 2018-01-09 AU AU2018206481A patent/AU2018206481A1/en active Pending
- 2018-01-09 PT PT187041017T patent/PT3565844T/pt unknown
- 2018-01-09 TW TW107100822A patent/TWI767976B/zh active
- 2018-01-09 US US16/476,536 patent/US11407830B2/en active Active
- 2018-01-09 IL IL267804A patent/IL267804B1/en unknown
- 2018-01-09 PL PL18704101.7T patent/PL3565844T3/pl unknown
- 2018-01-09 CA CA3049440A patent/CA3049440A1/en active Pending
- 2018-01-09 ES ES18704101T patent/ES2945745T3/es active Active
- 2018-01-09 FI FIEP18704101.7T patent/FI3565844T3/fi active
- 2018-01-09 SG SG11201906192SA patent/SG11201906192SA/en unknown
- 2018-01-09 MA MA047208A patent/MA47208A/fr unknown
- 2018-01-09 JP JP2019537103A patent/JP7110206B6/ja active Active
- 2018-01-09 HU HUE18704101A patent/HUE061842T2/hu unknown
- 2018-01-09 BR BR112019014187-1A patent/BR112019014187A2/pt unknown
- 2018-01-09 KR KR1020197023407A patent/KR102606252B1/ko active IP Right Grant
- 2018-01-09 EP EP18704101.7A patent/EP3565844B8/de active Active
- 2018-01-09 EP EP23158731.2A patent/EP4219563A3/de active Pending
- 2018-01-09 MX MX2019008207A patent/MX2019008207A/es unknown
- 2018-01-09 DK DK18704101.7T patent/DK3565844T3/da active
- 2018-01-09 SG SG10201913075RA patent/SG10201913075RA/en unknown
-
2019
- 2019-06-28 ZA ZA2019/04316A patent/ZA201904316B/en unknown
-
2022
- 2022-04-11 JP JP2022065095A patent/JP2022082809A/ja active Pending
- 2022-07-15 US US17/812,933 patent/US20230111418A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TWI767976B (zh) | 2022-06-21 |
KR20190114996A (ko) | 2019-10-10 |
CN110382545A (zh) | 2019-10-25 |
EP4219563A3 (de) | 2023-10-04 |
ZA201904316B (en) | 2022-12-21 |
HUE061842T2 (hu) | 2023-08-28 |
MX2019008207A (es) | 2019-12-11 |
SG10201913075RA (en) | 2020-02-27 |
IL267804B1 (en) | 2024-05-01 |
TW201831200A (zh) | 2018-09-01 |
EP3565844B8 (de) | 2023-04-12 |
EP4219563A2 (de) | 2023-08-02 |
IL267804A (en) | 2019-09-26 |
EP3565844A1 (de) | 2019-11-13 |
MA47208A (fr) | 2019-11-13 |
BR112019014187A2 (pt) | 2020-02-11 |
PL3565844T3 (pl) | 2023-06-12 |
US11407830B2 (en) | 2022-08-09 |
AU2018206481A1 (en) | 2019-07-25 |
ES2945745T3 (es) | 2023-07-06 |
JP2022082809A (ja) | 2022-06-02 |
JP7110206B6 (ja) | 2022-08-25 |
US20200239574A1 (en) | 2020-07-30 |
CA3049440A1 (en) | 2018-07-12 |
JP7110206B2 (ja) | 2022-08-01 |
JP2020504141A (ja) | 2020-02-06 |
WO2018129559A1 (en) | 2018-07-12 |
KR102606252B1 (ko) | 2023-11-23 |
PT3565844T (pt) | 2023-05-02 |
FI3565844T3 (fi) | 2023-05-09 |
EP3565844B1 (de) | 2023-03-01 |
US20230111418A1 (en) | 2023-04-13 |
DK3565844T3 (da) | 2023-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201906200WA (en) | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
SG11201906319XA (en) | Compositions and methods for the depletion of cd137+ cells |